Anthem Biosciences IPO allotment out today; GMP strong ahead of listing

The allotment status of Anthem Biosciences, the Bengaluru-based contract research and manufacturing company, will be finalised on Thursday. Applicants can now check their allotment details on the registrar’s website — KFin Technologies — by entering their PAN, application number or client ID.

The Rs 3,395 crore IPO — purely an offer for sale (OFS) of 5.96 crore equity shares — saw strong investor participation, particularly from qualified institutional buyers (QIBs).

The issue was subscribed 67.42 times overall, with QIBs bidding 192.8 times, non-institutional investors (NIIs) 44.7 times, and retail investors 5.98 times. The employee quota also saw healthy demand, subscribed nearly 7 times.

How to check Anthem Biosciences IPO allotment:

On KFin Technologies: https://kfintech.com

Go to “IPO Allotment Status”

Select “Anthem Biosciences Ltd.”

Enter PAN, application number, or DP/client ID

On BSE: https://www.bseindia.com/investors/appli_check.aspx

Select “Equity”

Choose “Anthem Biosciences Ltd.”

Enter application number and PAN

Refunds for non-allottees will be initiated on Friday, with shares credited to demat accounts the same day. The company is expected to make its stock market debut on Monday on both NSE and BSE.

GMP signals strong debut

The grey market premium (GMP) for Anthem Biosciences is currently hovering around Rs 154, translating to a 27% listing gain over the issue price of Rs 570. This suggests an expected listing price of around Rs 724, although actual performance will depend on market conditions on debut day.

About the company

Anthem Biosciences is one of India’s leading contract research, development, and manufacturing organizations (CRDMO), catering to global biotech and pharma clients.

It reported a 23% YoY jump in net profit to Rs 451 crore in FY25, on a revenue base of Rs 1,930 crore. EBITDA margin stood at a robust 36.8%, reflecting healthy operational performance.

While the IPO was entirely an OFS and the company won’t receive any proceeds, analysts remain optimistic about its long-term growth, given its innovation-driven business model and global customer base.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)